TERT promoter gene mutations are highly recurrent in malignant glioma. However, little information exists regarding their presence in experimental brain tumor models. To better characterize systems in which TERT mutation studies could be appropriately modeled experimentally, the TERT promoter was examined by conventional sequencing in primary brain tumor initiating cells (BTIC), two matched recurrent BTIC lines, a panel of established malignant glioma cell lines, and two meningioma cell lines. Telomerase gene expression was examined by quantitative PCR. We found that all glioblastoma BTIC lines harbored a TERT mutation, which was retained in two patient-matched recurrent BTIC. The TERT C228T or C250T mutation was found in 33/35 (94 %) of established malignant glioma cell lines and both meningioma cell lines examined. Brain tumor cell lines expressed variably high telomerase levels. Thus, a high percentage of glioma cell lines, as well as two meningioma cell lines, harbors TERT mutations. These data characterize tractable, accessible models with which to further explore telomerase biology in these tumor types.
TERTTelomerase Glioma Glioblastoma Meningioma Brain tumor initiating cells Cancer
This is a preview of subscription content, log in to check access.
The authors thank Dr. Ravi Uppaluri for reviewing this manuscript and Dr. Jeffrey Atkinson for technical assistance. This work was supported by NIH grant K08NS092912 (G.P.D.), NIH Grant K08NS081105 (A.H.K.), American Cancer Society-Institutional Research Grant (A.H.K., G.P.D), the Duesenberg Research Fund (A.H.K.), the Physician-Scientist Training Program at Washington University School of Medicine (T.M.J.), and the Brain Science Foundation (I.F.D.).
Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMedGoogle Scholar
Network TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068CrossRefGoogle Scholar
Killela PJ et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110(15):6021–6026CrossRefPubMedPubMedCentralGoogle Scholar
Arita H et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126(2):267–276CrossRefPubMedGoogle Scholar
Greider CW (2012) Molecular biology. Wnt regulates TERT—putting the horse before the cart. Science 336(6088):1519–1520CrossRefPubMedGoogle Scholar